MetaCap

BioAge Labs (BIOA) vs Faeth Therapeutics (FTH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Faeth Therapeutics (FTH) has outperformed BioAge Labs (BIOA) over the past year, losing 9.6% versus a loss of 50.5%. Faeth Therapeutics is the larger company by market cap ($203.7 million vs $196.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BIOA-50.52%FTH-9.64%
+380%+154%-71%
Nov 21, 20251 yearNov 20, 2026
BIOA-79.62%FTH-29.14%
+277%+88%-102%
Sep 23, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BIOA versus FTH key metrics
MetricBIOAFTH
Share price$4.28$7.88
Market cap$196.67M$203.65M
1-day change-9.13%-9.32%
YTD return-67.65%-26.15%
1-year return-50.52%-9.64%
5-year return—-94.96%
EPS (TTM)$-2.56$-22.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$8.99M—
Net income (latest FY)$-80.61M$-21.09M
Operating margin-1031.46%—
Net margin-896.11%—
52-week high$25.96$42.14
52-week low$4.24$7.45
Distance from 52-week high-83.51%-81.30%
Analyst consensusbuystrong_buy
Avg. price target upside+572.43%+612.56%
Average volume740.06K500.25K
Shares outstanding45.95M25.84M
Employees6029
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FTH has outperformed BIOA by 40.9 percentage points over the past year.

About BioAge Labs

BIOA stock →

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

About Faeth Therapeutics

FTH stock →

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

BIOA vs FTH FAQ

Which is bigger, BioAge Labs or Faeth Therapeutics?

Faeth Therapeutics (FTH) is larger, with a market capitalization of $203.65M compared with $196.67M for BioAge Labs (BIOA).

Which stock has performed better over the past year, BIOA or FTH?

FTH returned -9.64% over the past 12 months, compared with -50.52% for BIOA (price return, excluding dividends). Past performance does not predict future results.

Are BioAge Labs and Faeth Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons